CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Paramedic CoachingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D003704 Dementia NIH 0.50

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000726 Dementia HPO 0.50

There is one clinical trial.

Clinical Trials

1 Community Paramedic Coaching Program for Caregivers and People With Dementia (CP3D)

This pilot study is designed to evaluate the potential effectiveness of the implementation strategy and intervention delivery model of a community paramedic coaching program for caregivers of persons with dementia, in direct coordination with the participant and caregiver's primary health care team. Specifically, the acceptability, appropriateness, and feasibility of the program will be assessed, collecting data from all implementation stakeholders at baseline, 13 weeks, 25 weeks, and post-intervention (~50 weeks) using quantitative survey instruments and qualitative interviews.

NCT04239924 Dementia Behavioral: Paramedic Coaching
MeSH:Dementia
HPO:Dementia

Primary Outcomes

Description: As determined by abstracting the medical records, the investigators are testing the hypothesis that the number of visits to the Emergency Department is lower than commonly reported in the literature for persons with dementia.

Measure: Number of Visits to the Emergency Department by the Person with Dementia

Time: up to 24 months

Description: As determined by abstracting the medical records, the investigators are testing the hypothesis that the number of visits to the Emergency Department is lower than commonly reported in the literature for average older adults.

Measure: Number of Visits to the Emergency Department by the Caregiver of the Person with Dementia

Time: up to 24 months

Description: The intervention will be deemed feasible if at least 75% of the intended coaching phone calls are completed. The minimum number of coaching calls is 3, additional calls will be scheduled opposite weeks of home visits as needed.

Measure: Feasibility: Proportion of Coaching Phone Calls Completed

Time: up to 12 months

Description: The intervention will be deemed feasible if at least 75% of the intended home visits are completed. The minimum number of intended home visits is 9.

Measure: Feasibility: Proportion of Coaching Home Visits Completed

Time: up to 12 months

Secondary Outcomes

Description: The Zarit Burden Interview measures caregiver burden. This is a 12-item survey with a total possible range of scores from 0-48, where higher scores indicate increased burden. The investigators hypothesize the score will decrease as a result of the intervention.

Measure: Change in Zarit Burden Interview (ZBI-12) Score

Time: First home visit (~ week 1), week 13, week 25, and last home visit (~up to week 50)

Description: The GAD-7 is a 7-item survey that measures anxiety symptom severity. The total possible range of scores is 0-21, where higher scores indicate increased symptom severity. The investigators hypothesize the score will decrease as a result of the intervention.

Measure: Change in Generalized Anxiety Disorder (GAD-7) Score

Time: Baseline, week 13, week 25, week 50

Description: The CESD-10 is a general measure of depression frequently used in caregiver studies. It is a 10-item survey with a total possible range of scores of 0-30 where higher scores indicate increased depression. The investigators hypothesize the score will decrease as a result of the intervention.

Measure: Change in Center for Epidemiologic Studies Depression Scale (CESD-10)

Time: First home visit (~ week 1), week 13, week 25, and last home visit (~up to week 50)

Description: The RCSS is a 6-item survey used to measure the positive aspects of caring. The range of total possible scores is 6-30 where higher scores indicate increased caregiver satisfaction. The investigators hypothesize the score will increase as a result of the intervention.

Measure: Change in Revised Caregiving Satisfaction Scale (RCSS)

Time: Baseline, week 13, week 25, week 50

Description: The revised scale for caregiving self-efficacy measures three domains: obtaining respite, responding to disruptive patient behaviors, and controlling upsetting thoughts. It is a 15-item scale with a total possible range of scores between 0-100, where higher scores are better. The investigators hypothesize the score will increase as a result of the intervention.

Measure: Change in Revised Scale for Caregiving Self-Efficacy

Time: First home visit (~ week 1) and last home visit (~up to week 50)

Description: WFC is measured for the caregiver. It is a 6-item survey with a total possible range of scores between 6-30 with higher scores indicating lesser work-family conflict. The investigators hypothesize the score will increase as a result of the intervention.

Measure: Change in Work-Family Conflict Scale (WFC)

Time: First home visit (~ week 1) and last home visit (~up to week 50)

Description: C-DEMQOL is measured for the caregiver. The investigators will be asking 18 of the questions from the scale to understand the quality of life the caregivers experience. Scores can range from 18-90, with a higher score reflecting a higher quality of life.

Measure: Change in Caregiver Quality of Life (C-DEMQOL) Score

Time: Baseline and 62 weeks (12 weeks post completion)

Description: DKAS is measured for the caregiver. It is a 25 item true-false survey of facts about dementia. Scoring is by measuring the proportion of questions answered correctly.

Measure: Change in Knowledge of Dementia (DKAS) Score

Time: Baseline and 62 weeks (12 weeks post completion)

Description: As determined by abstracting the medical records, the investigators are characterizing the number of contacts with outpatient clinics for persons with dementia.

Measure: Clinic Utilization by Persons with Dementia

Time: up to 24 months

Description: As determined by abstracting the medical records, the investigators are characterizing the number of contacts with outpatient clinics for caregivers of persons with dementia.

Measure: Clinic Utilization by Caregivers of Persons with Dementia

Time: up to 24 months

Description: Assesses caregivers perception of communication with health care team and extent to which the team considers their capacity and preferences in decision making. This measure consists of 12 questions, with scores ranging from 12-60, where higher scores indicate increased communication with the health care team.

Measure: Change in Caregiver Perceptions About Communication With Clinical Team Members (CAPACITY) Measure

Time: Baseline and 62 weeks (12 weeks post completion)

Related HPO nodes (Using clinical trials)

HP:0000726: Dementia
Genes 290
C9ORF72 HNRNPA2B1 DNAJC13 HTT CHCHD10 HNRNPA1 CLN6 FMR1 PSAP ATXN10 TOMM40 GBA ATXN3 PSEN1 ADH1C GBA2 CHMP2B COX1 TREM2 POLG NOTCH3 PLAU TRNF AARS2 PINK1 VPS13C TBP SYNJ1 MAPT ATXN8OS UCHL1 PSEN1 SNCA FUS TYMP SLC13A5 TRNC PLA2G6 MATR3 EPM2A SNCA C19ORF12 PANK2 SNCA CP PPP2R2B CHMP2B HTT TRNK TRNL1 ND1 ND4 PDGFB RRM2B NR4A2 ERCC8 MPO VPS13A LRRK2 SERPINI1 JPH3 PODXL GIGYF2 ITM2B WDR45 PRNP COX3 TRNQ DNMT1 SPAST SDHB ABCD1 C9ORF72 PRNP GBA PSEN2 NPC2 LRRK2 SQSTM1 GBA TRPM7 CYTB SNCA TRNV MAPT RNF216 HTRA1 COX3 COL4A1 CYP27A1 GRN FTL FMR1 TUBA4A TWNK APP ALDH18A1 MMACHC VPS13C MAPT MBTPS2 TMEM106B SQSTM1 ATP13A2 SPG21 ATN1 APTX GBA HEXA ATP6V0A2 PARK7 ALDH18A1 WDR45 DGUOK HTRA2 ARSA NOTCH2NLC TRNS2 ROGDI MAPT KCTD7 WFS1 TREM2 CISD2 TRNQ VPS35 APOE GBA PRNP PSEN2 HTT TBP HFE CLN3 NHLRC1 TRNS1 UBQLN2 GRN CHCHD10 PNPLA6 TRNH VCP SDHD HTRA1 TYROBP ZFYVE26 HNRNPA2B1 NPC1 TREM2 C9ORF72 SLC2A3 PSEN1 MAPT TYROBP TARDBP CP TREM2 PANK2 DNMT1 RNF216 PINK1 MATR3 ATP6V1A PLA2G6 SNCA SDHAF1 MAPT GRN CSF1R TTR XPR1 COX2 TRNF SDHA VCP SNCAIP SORL1 LRRK2 GRN ATXN2 TARDBP SCARB2 TRNW ATP7B APP GM2A PRDM8 TBK1 PDGFRB PRICKLE1 ATP13A2 IRF6 APOE ROGDI POLG PSEN1 ATXN2 CHMP2B PSEN1 APP PRKAR1B VCP ATP13A2 PRNP ITM2B ATP6 NHLRC1 ATP13A2 TBK1 TRNS2 ASAH1 NOS3 APP A2M EPM2A CSTB DNAJC5 COX1 CTSF CERS1 CHMP2B SQSTM1 WFS1 TRNW TUBB4A APP ATN1 PRNP ND5 C9ORF72 JPH3 SPG21 RAB39B PRKN ND6 MAPT ATXN2 DCTN1 ND5 ABCA7 APP SNCB CUBN PRNP PRNP FBXO7 ERCC4 HLA-DQB1 PSEN1 NDP C9ORF72 TREX1 DCTN1 PRDX1 PPP2R2B VCP TMEM106B SNCA CFAP43 PSEN1 VCP TRNE GBA2 APP NOTCH3 TRNS1 COX2 ATP6V1E1 TREM2 TIMM8A FTL VCP CHMP2B MAPT MECP2 ATP6 MAPT TMEM106B EIF4G1 DNM1L ND6 ADA2 ASAH1 GBE1 TRNL1 CST3 ND1 GLUD2 OPA1 DNAJC6
Protein Mutations 1
V158M
SNP 0